JMP Securities' Jason Butler jumps to Keryx's (KERX -0.7%) defense today after the stock... Monday, February 4, 8:44 AM ET JMP Securities' Jason Butler jumps to Keryx's (KERX -0.7%) defense today after the stock plummeted 22% on Friday following a report from research firm IPD Analytics that questioned whether the FDA will grant the company New Chemical Entity status for its Zerenex treatment for patients undergoing dialysis. IDP reckons that the active ingredient in Zerenex may be too similar to an existing chemical called Ferriseltz, although Butler begs to differ. ________________________________________________________
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.